ossn-diamonds-nos-left

Providing a VOICE for Nevada's MULTIDISCIPLINARY CANCER CARE TEAMS and the PATIENTS THEY SERVE since 1993

ossn-diamonds-nos-right

Join
About
Meetings & Education
- Upcoming Events
Resources
Industry

Industry News Archive

FDA Approves Pembrolizumab + Axitinib for Advanced Renal Cell Carcinoma
FDA Expands Pembrolizumab Indication to Include First-Line NSCLC Treatment
FDA Expands Palbociclib Use to Include Male Breast Cancer Patients
HCPCS Assigns J-Code and ASP for Imfinzi
FDA Approves Trastuzumab-qyyp as Biosimilar to Herceptin
FDA Approves Pembrolizumab for Melanoma
Medicare Coverage Established for MRD Testing for ALL, Multiple Myeloma
FDA Approves Olaparib for Ovarian, Fallopian, Peritoneal Cancers
FDA Approves Pembrolizumab for Merkel Cell Carcinoma
CMS Assigns Unique HCPCS Code for Imfinzi
FDA Approves Glasdegib for Acute Myeloid Leukemia
Imfinzi Assigned Unique HCPCS Code for Reimbursement by CMS
FDA Approves Pembrolizumab for Hepatocellular Carcinoma
FDA Approves Elotuzumab, Pomalidomide, Dexamethasone for Multiple Myeloma
FDA Approves Lorlatinib for ALK+ Metastatic NSCLC
FDA Approves Pembrolizumab for First-Line Treatment of Metastatic Squamous NSCLC
FDA Approves Talazoparib for gBRCAm HER2- Breast Cancer
FDA Expands Approval of HPV Vaccine to People Aged 27 to 45
Imfinzi Demonstrates Overall Survival Benefit in Stage III Lung Cancer
FDA Approves Dacomitinib for Metastatic NSCLC
FDA Approves New Treatment for Hairy Cell Leukemia
FDA Approves Pembrolizumab + Chemotherapy for NSqNSCLC
FDA Approves Nivolumab for Previously Treated SCLC Patients
FDA Approves Ribociclib in Combination for Advanced, Metastatic Breast Cancer
FDA Approves Nivolumab Plus Ipilimumab for Metastatic Colorectal Cancer
CMS Posts MIPS Final Scores, Performance Feedback for Review
FDA Restricts Use of Keytruda and Tecentriq for Urothelial Cancer
Pfizer’s Biosimilar Retacrit® Receives Q-Codes
FDA Approves Pembrolizumab for Treatment of PMBCL
FDA Approves Pembrolizumab for Advanced Cervical Cancer
Pfizer’s Biosimilar RETACRIT® (epoetin alfa-epbx) Approved by U.S. FDA
CMS Begins Mailing Out New Medicare Cards
Trump Administration Announces MyHealthEData Initiative

Tweets by NV_Oncology

Contact Us

Get Connected

1801 Research Boulevard Suite 400
Rockville, MD 20850
Tel: 301.984.9496 | Fax: 301.770.1949
nos-nevada.com
Email Us

Engage & Succeed

Copyright © 2019 Oncology State Societies at ACCC. All rights reserved. Privacy Policy